{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:40:43Z","timestamp":1787614843127,"version":"build-2736575974"},"reference-count":31,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: The combination of venetoclax (VEN) and hypomethylating agents (HMA), such as azacitidine (AZA) or decitabine (DEC), has transformed the treatment landscape for acute myeloid leukemia (AML) in patients unfit for intensive chemotherapy. However, optimal management of neutropenia and the impact of post-remission treatment interruptions (washouts) remain unclear. This study aimed to evaluate the safety and efficacy of post-remission washouts and their effect on clinical outcomes. Methods: We conducted a retrospective single-center study of 44 AML patients treated with HMA\/VEN between 2020 and 2021. Clinical, molecular, and treatment-related data were collected, including treatment duration, post-remission washout duration, response rates, disease-free survival (DFS), and overall survival (OS). Statistical analyses included Fisher\u2019s exact test and univariate and multivariate Cox models. Results: Overall, 61% of patients responded to therapy, with significantly higher response rates among those potentially eligible for the VIALE-A trial (86% vs. 39%, p = 0.002). Neither treatment duration nor post-remission washout length was associated with DFS or OS. DFS was significantly longer in patients treated with AZA compared to DEC (p = 0.006). Median OS was 7.7 months, with longer OS observed in patients who met VIALE-A trial eligibility criteria (p = 0.021). Achieving complete remission (CR) was associated with improved OS (14.5 months). Conclusions: Post-remission treatment interruptions (washouts) did not negatively impact DFS or OS, suggesting they may be a safe strategy to support hematologic recovery. However, the choice of HMA appears to influence response duration, with AZA outperforming DEC in maintaining disease control.<\/jats:p>","DOI":"10.3390\/jcm14145007","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T15:01:05Z","timestamp":1752591665000},"page":"5007","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Length of Washout Period After Remission Does Not Influence Relapse Risk in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents Combined with Venetoclax"],"prefix":"10.3390","volume":"14","author":[{"given":"Fanny","family":"Palumbo","sequence":"first","affiliation":[{"name":"Division of Hematology, A.O.U. Policlinico \u201cG.Rodolico\u2014S. Marco\u201d, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9510-4755","authenticated-orcid":false,"given":"Andrea","family":"Duminuco","sequence":"additional","affiliation":[{"name":"Division of Hematology, A.O.U. Policlinico \u201cG.Rodolico\u2014S. Marco\u201d, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Longo","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Program\/Regional Pharmacovigilance Centre, A.O.U. Policlinico \u201cG.Rodolico\u2014S. Marco\u201d, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4957-958X","authenticated-orcid":false,"given":"Daniela","family":"Vitale","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Program\/Regional Pharmacovigilance Centre, A.O.U. Policlinico \u201cG.Rodolico\u2014S. Marco\u201d, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Maugeri","sequence":"additional","affiliation":[{"name":"Division of Hematology, A.O.U. Policlinico \u201cG.Rodolico\u2014S. Marco\u201d, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Brancati","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Program\/Regional Pharmacovigilance Centre, A.O.U. Policlinico \u201cG.Rodolico\u2014S. Marco\u201d, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Parisi","sequence":"additional","affiliation":[{"name":"Division of Hematology, A.O.U. Policlinico \u201cG.Rodolico\u2014S. Marco\u201d, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1859-6319","authenticated-orcid":false,"given":"Giuseppe","family":"Palumbo","sequence":"additional","affiliation":[{"name":"Division of Hematology, A.O.U. Policlinico \u201cG.Rodolico\u2014S. Marco\u201d, 95123 Catania, Italy"},{"name":"Department of Scienze Mediche Chirurgiche e Tecnologie Avanzate \u201cG.F. Ingrassia\u201d, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8722-7835","authenticated-orcid":false,"given":"Giovanni","family":"Romano","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Surgery, University of Enna \u201cKore\u201d, 94100 Enna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Drago","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Program\/Regional Pharmacovigilance Centre, A.O.U. Policlinico \u201cG.Rodolico\u2014S. Marco\u201d, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Di Raimondo","sequence":"additional","affiliation":[{"name":"Division of Hematology, A.O.U. Policlinico \u201cG.Rodolico\u2014S. Marco\u201d, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7512-269X","authenticated-orcid":false,"given":"Lucia","family":"Gozzo","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Program\/Regional Pharmacovigilance Centre, A.O.U. Policlinico \u201cG.Rodolico\u2014S. Marco\u201d, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1922-5157","authenticated-orcid":false,"given":"Calogero","family":"Vetro","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplantation Unit, Hospital of Bolzano (SABES-Azienda Sanitaria dell\u2019Alto Adige), Teaching Hospital of Paracelsus Medical University, 39100 Bolzano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Gozzo, L., Vetro, C., Brancati, S., Longo, L., Vitale, D.C., Romano, G.L., Mauro, E., Fiumara, P.F., Maugeri, C., and Parisi, M.S. (2021). Off-Label Use of Venetoclax in Patients with Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.748766"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1182\/blood.2024024009","article-title":"How I Treat Patients with AML Using Azacitidine and Venetoclax","volume":"145","author":"Wei","year":"2025","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00280-024-04673-5","article-title":"Overexposure to Venetoclax Is Associated with Prolonged-Duration of Neutropenia during Venetoclax and Azacitidine Therapy in Japanese Patients with Acute Myeloid Leukemia","volume":"94","author":"Kobayashi","year":"2024","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Duminuco, A., Del Fabro, V., De Luca, P., Leotta, D., Limoli, M.C., Longo, E., Nardo, A., Santuccio, G., Petronaci, A., and Stanzione, G. (2024). Emergencies in Hematology: Why, When and How I Treat?. J. Clin. Med., 13.","DOI":"10.3390\/jcm13247572"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1002\/cncr.33508","article-title":"Duration of Cytopenias with Concomitant Venetoclax and Azole Antifungals in Acute Myeloid Leukemia","volume":"127","author":"Rausch","year":"2021","journal-title":"Cancer"},{"key":"ref_7","unstructured":"Myeloid Group (2025, July 11). ML.84\u2014Azacitidine and Venetoclax. Treatment Protocol for Adult AML When Intensive Chemotherapy Is Unsuitable (NICE TA 765). National Cancer Research Institute (NCRI), Oxford University Hospitals NHS Foundation Trust; Version 3.1, March 2024. Available online: https:\/\/nssg.oxford-haematology.org.uk."},{"key":"ref_8","unstructured":"(2025, July 11). CHMP ALLEGATO I RIASSUNTO DELLE CARATTERISTICHE DEL PRODOTTO. Available online: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2016\/20161205136381\/anx_136381_it.pdf."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"400","DOI":"10.6004\/jadpro.2022.13.4.4","article-title":"Practical Management of the Venetoclax-Treated Patient in Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia","volume":"13","author":"Waggoner","year":"2022","journal-title":"J. Adv. Pract. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of Cytogenetic Classification in Acute Myeloid Leukemia: Determination of Prognostic Significance of Rare Recurring Chromosomal Abnormalities among 5876 Younger Adult Patients Treated in the United Kingdom Medical Research Council Trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Duminuco, A., Maugeri, C., Parisi, M., Mauro, E., Fiumara, P.F., Randazzo, V., Salemi, D., Agueli, C., Palumbo, G.A., and Santoro, A. (2022). Target Therapy for Extramedullary Relapse of FLT3-ITD Acute Myeloid Leukemia: Emerging Data from the Field. Cancers, 14.","DOI":"10.3390\/cancers14092186"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/leu.2012.303","article-title":"Consensus-Based Definition of Unfitness to Intensive and Non-Intensive Chemotherapy in Acute Myeloid Leukemia: A Project of SIE, SIES and GITMO Group on a New Tool for Therapy Decision Making","volume":"27","author":"Ferrara","year":"2013","journal-title":"Leukemia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1001\/jamaoncol.2017.2714","article-title":"Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality","volume":"3","author":"Sorror","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_14","unstructured":"(2025, July 11). Committee for Medicinal Products for Human Use (CHMP) EMA\/CHMP\/206516\/2021. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/smop\/chmp-post-authorisation-summary-positive-opinion-venclyxto-ii-30_en.pdf."},{"key":"ref_15","unstructured":"(2025, July 11). Agenzia Italiana del Farmaco (AIFA) Determina 27 Marzo 2023, n. 248\/2023\u2014Regime Di Rimborsabilit\u00e0 e Prezzo Del Medicinale per Uso Umano \u201cVenclyxto\u201d (Venetoclax) 2023, Available online: https:\/\/www.aifa.gov.it\/documents\/20142\/961234\/determina_248-2023_venclyxto.pdf."},{"key":"ref_16","unstructured":"(2025, July 11). Gazzetta Ufficiale della Repubblica Italiana Legge 5 Marzo 2020, n. 13\u2014Conversione in Legge, Con Modificazioni, Del Decreto-Legge 23 Febbraio 2020, n. 6, Recante Misure Urgenti in Materia Di Contenimento e Gestione Dell\u2019emergenza Epidemiologica Da COVID-19. 2020, pp. 140\u2013141. Available online: https:\/\/www.gazzettaufficiale.it\/eli\/gu\/2020\/03\/09\/62\/sg\/pdf."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1182\/blood-2023-178505","article-title":"Real World Outcome of Unfit Patients with Acute Myeloid Leukemia Treated with the Combination Venetoclax Plus Hypomethylating Agents in the Gimema AML2320 Observational Trial","volume":"142","author":"Venditti","year":"2023","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2024-193999","article-title":"Therapy Management and Outcomes in Newly Diagnosed Unfit AML Patients Receiving Venetoclax + HMA\u2014Insights from a Prospective Real-World Study in Switzerland and Austria","volume":"144","author":"Pabst","year":"2024","journal-title":"Blood"},{"key":"ref_19","unstructured":"(2025, July 11). Gazzetta Ufficiale della Repubblica Italiana. Determina 3 febbraio 2020, n. 12137\/2020\u2014Inserimento del Medicinale \u201cVenetoclax\u201d, in Combinazione con \u201cAzacitidina\u201d o \u201cDecitabina\u201d, Nell\u2019elenco dei Medicinali Erogabili a Totale Carico del Servizio Sanitario Nazionale ai Sensi Della Legge 23 Dicembre 1996, n. 648, per il Trattamento di Pazienti Adulti con Leucemia Mieloide Acuta di Nuova Diagnosi non Candidabili a Chemioterapia Intensiva di Induzione o con et\u00e0 \u226575 anni. G.U. Serie Generale n. 61, 9 March 2020. Available online: https:\/\/www.gazzettaufficiale.it\/eli\/id\/2020\/03\/09\/20A01496\/sg."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41408-022-00668-8","article-title":"Venetoclax Combinations Delay the Time to Deterioration of HRQoL in Unfit Patients with Acute Myeloid Leukemia","volume":"12","author":"Pratz","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1182\/blood-2023-180568","article-title":"SIE\/Sies\/GITMO Criteria in Elderly Patients with Acute Myeloid Leukemia (AML): Useful Also in the New Drug Era? A Multicentric Real-Life Study By the Hematological Network Rete Ematologica Lombarda (REL)","volume":"142","author":"Borlenghi","year":"2023","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","article-title":"Long-Term Follow-up of VIALE-A: Venetoclax and Azacitidine in Chemotherapy-Ineligible Untreated Acute Myeloid Leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/ajh.27515","article-title":"The Impact of Post-Remission Granulocyte Colony-Stimulating Factor Use in the Phase 3 Studies of Venetoclax Combination Treatments in Patients with Newly Diagnosed Acute Myeloid Leukemia","volume":"100","author":"DiNardo","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"E416","DOI":"10.1002\/ajh.26692","article-title":"Postremission Cytopenia Management in Patients with Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine in VIALE-A","volume":"97","author":"Pratz","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Sch\u00fcpbach, A., Akhoundova, D., Bacher, U., Nilius, H., Hoffmann, M., Largiad\u00e8r, C.R., Aebi, Y., Hayoz, M., Kronig, M.-N., and Pabst, T. (2025). Impact of Venetoclax Treatment Schedule on Hematologic Recovery and Treatment Response in AML Patients Unfit for Intensive Chemotherapy. Cancers, 17.","DOI":"10.3390\/cancers17071138"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"6063","DOI":"10.1182\/blood-2024-200013","article-title":"Evaluation of Venetoclax Duration in Venetoclax-Azacitidine Regimen for Untreated Acute Myeloid Leukemia: Real World Experience from Hokkaido Leukemia Net","volume":"144","author":"Kanaya","year":"2024","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00277-023-05102-y","article-title":"Shorter Duration of Venetoclax Administration to 14 Days Has Same Efficacy and Better Safety Profile in Treatment of Acute Myeloid Leukemia","volume":"102","author":"Aiba","year":"2023","journal-title":"Ann. Hematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1182\/bloodadvances.2022007083","article-title":"Treatment-Free Remission after Ceasing Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia","volume":"6","author":"Chua","year":"2022","journal-title":"Blood Adv."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1182\/blood-2023-185437","article-title":"Acute Myeloid Leukemia Patients Who Stopped Venetoclax or\/and Azacytidine for Other Reasons Than Progression Have a Prolonged Treatment Free Remission and Overall Survival. a Filo Study","volume":"142","author":"Garciaz","year":"2023","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"17914","DOI":"10.1002\/cam4.6430","article-title":"Post-Remission Cytopenia Management in Patients with AML Treated with Venetoclax in Combination with Hypomethylating Agents: Pre- versus Post-VIALE-A Real-World Experience from a Predominantly US Community Setting","volume":"12","author":"Vachhani","year":"2023","journal-title":"Cancer Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.11648\/j.ajtas.20160501.11","article-title":"Comparison of Convenience Sampling and Purposive Sampling","volume":"5","author":"Etikan","year":"2016","journal-title":"Am. J. Theor. Appl. Stat."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/14\/5007\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T10:40:11Z","timestamp":1763116811000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/14\/5007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":31,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["jcm14145007"],"URL":"https:\/\/doi.org\/10.3390\/jcm14145007","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]}}}